Braveheart Bio (NASDAQ:BRVE – Get Free Report) released its earnings results on Tuesday. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.40, Zacks reports.
Braveheart Bio Stock Up 0.8%
BRVE opened at $19.62 on Wednesday. Braveheart Bio has a 12 month low of $16.70 and a 12 month high of $32.00. The business has a 50 day simple moving average of $22.44.
Analysts Set New Price Targets
Several equities analysts have weighed in on BRVE shares. Weiss Ratings started coverage on Braveheart Bio in a report on Monday, November 2nd. They set a “sell (d-)” rating for the company. Wall Street Zen raised Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. Zacks Research upgraded Braveheart Bio to a “hold” rating in a research note on Tuesday, September 1st. Stifel Nicolaus began coverage on Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $45.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 price target on shares of Braveheart Bio in a research note on Tuesday, October 20th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.25.
Get Our Latest Report on Braveheart Bio
Braveheart Bio Company Profile
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Featured Stories
- Five stocks we like better than Braveheart Bio
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
- The Trade Desk Beats on Revenue, But the Fine Print Matters
- Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.
